Viva Biotech Holdings submitted its Monthly Return for Equity Issuer to Hong Kong Exchanges and Clearing Limited for the period ended 31 March 2026. Key takeaways are as follows:

1. Authorised Share Capital • Authorised ordinary shares remained unchanged at 4.00 billion with a par value of USD 0.000025, translating to authorised share capital of USD 0.10 million.

2. Issued Shares and Public Float • Issued ordinary shares stood at 2.13 billion, identical to the previous month. • The company held no treasury shares. • Viva Biotech confirmed compliance with the minimum 25% public-float requirement.

3. Share-Based Incentives • Pre-IPO Share Incentive Schemes: 2.22 million options outstanding; no grants, exercises, cancellations or lapses in March. • Post-IPO Share Option Scheme: 13.70 million options outstanding; no activity recorded during the month. • Total options outstanding across both schemes: 15.92 million. • An additional 124.35 million shares remain available for future grants under the Post-IPO scheme. • No new shares were issued and no funds were raised from option exercises in March 2026.

4. Other Securities • The company reported no warrants, convertibles, Hong Kong depositary receipts, or other share-issuance arrangements during the month.

Viva Biotech’s filing reiterates that all procedural confirmations under Hong Kong’s Listing Rules have been completed, with Executive Director Mao Chen Cheney signing the submission on 9 April 2026.